Jane Street Group LLC raised its stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 234.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 72,454 shares of the company's stock after buying an additional 50,808 shares during the period. Jane Street Group LLC owned approximately 0.39% of OptimizeRx worth $352,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new position in shares of OptimizeRx during the 4th quarter worth approximately $25,000. SG Americas Securities LLC purchased a new position in shares of OptimizeRx during the 4th quarter worth approximately $51,000. Wells Fargo & Company MN increased its stake in shares of OptimizeRx by 33.3% during the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock worth $54,000 after purchasing an additional 2,797 shares in the last quarter. Barclays PLC increased its stake in shares of OptimizeRx by 13.5% during the 4th quarter. Barclays PLC now owns 30,574 shares of the company's stock worth $148,000 after purchasing an additional 3,640 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of OptimizeRx during the 4th quarter worth approximately $178,000. 76.47% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at OptimizeRx
In other OptimizeRx news, Director James Paul Lang acquired 321,408 shares of OptimizeRx stock in a transaction dated Friday, March 14th. The stock was acquired at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the transaction, the director now owns 389,452 shares in the company, valued at approximately $2,959,835.20. This represents a 472.35% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 5.60% of the stock is currently owned by insiders.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on the stock. Roth Capital reissued a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. JMP Securities lifted their target price on shares of OptimizeRx from $11.00 to $14.00 and gave the stock a "market outperform" rating in a research note on Tuesday, May 13th. Stifel Nicolaus lifted their target price on shares of OptimizeRx from $8.00 to $12.50 and gave the stock a "buy" rating in a research note on Tuesday, May 13th. B. Riley reaffirmed a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Finally, Citigroup reaffirmed an "outperform" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.38.
Check Out Our Latest Research Report on OPRX
OptimizeRx Stock Up 2.9%
Shares of NASDAQ:OPRX traded up $0.40 during midday trading on Thursday, hitting $14.18. 1,039,025 shares of the company's stock traded hands, compared to its average volume of 288,067. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The company has a market cap of $262.26 million, a PE ratio of -10.66 and a beta of 1.28. The firm's fifty day moving average price is $9.86 and its two-hundred day moving average price is $7.15. OptimizeRx Co. has a twelve month low of $3.78 and a twelve month high of $15.08.
OptimizeRx (NASDAQ:OPRX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.19. The firm had revenue of $21.93 million for the quarter, compared to the consensus estimate of $18.69 million. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. On average, equities research analysts anticipate that OptimizeRx Co. will post -0.33 EPS for the current fiscal year.
About OptimizeRx
(
Free Report)
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Featured Articles
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
